- Home
- REFI vs VYGR Comparison
REFI vs VYGR Comparison
Compare REFI & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | REFI | VYGR |
|---|---|---|
| Founded | 2021 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 255.6M | 222.4M |
| IPO Year | 2021 | 2015 |
Fundamental Metrics
Financial Performance| Metric | REFI | VYGR |
|---|---|---|
| Price | $12.36 | $3.89 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $20.00 | $17.00 |
| AVG Volume (30 Days) | 117.3K | ★ 667.5K |
| Earning Date | 03-11-2026 | 03-10-2026 |
| Dividend Yield | ★ 16.61% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.69 | N/A |
| Revenue | ★ $54,287,847.00 | $31,316,000.00 |
| Revenue This Year | $13.69 | N/A |
| Revenue Next Year | $3.55 | $71.78 |
| P/E Ratio | $7.32 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $11.85 | $2.65 |
| 52 Week High | $16.27 | $5.78 |
Technical Indicators
Market Signals| Indicator | REFI | VYGR |
|---|---|---|
| Relative Strength Index (RSI) | 47.61 | 45.43 |
| Support Level | $12.13 | $3.86 |
| Resistance Level | $12.41 | $4.11 |
| Average True Range (ATR) | 0.23 | 0.25 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 40.19 | 47.79 |
Price Performance
Historical ComparisonAbout REFI Chicago Atlantic Real Estate Finance Inc.
Chicago Atlantic Real Estate Finance Inc is engaged in a commercial real estate finance company. Its primary investment objective is to provide attractive risk-adjusted returns for stockholders over time, through consistent current income dividends and other distributions and secondarily through capital appreciation.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.